Stevanato Group's fourth-quarter performance exceeded expectations, with the stock soaring nearly 17%

LootboxPhobia · 2026-03-04T21:38:35+00:00

Stevanato Group exceeded expectations in the fourth quarter, with earnings per share of €0.18 and revenue of €346.5 million. The stock rose 16.70% after hours. The company expects the FY2026 EPS guidance to be slightly below analyst expectations, with revenue in line with market expectations. Contributions from high-value solutions are significant.

LootboxPhobia

2026-03-04 21:38:35

Abstract generation in progress

Piedmontese Pionbinodese, Italy - On Wednesday, Stevanato Group S.p.A. (NYSE:STVN) announced fourth-quarter results that exceeded analyst expectations.

Following the earnings release, the company’s stock surged 16.70% in after-hours trading, driven by strong momentum in its high-value solutions business.

This Italian provider of drug containers and delivery solutions reported an adjusted diluted earnings per share of €0.18 for the quarter, surpassing the analyst consensus of €0.17.

Revenue increased 5% year-over-year (7% at constant exchange rates) to €346.5 million, beating the consensus estimate of €333.79 million and up from €330.6 million in the same period last year. High-value solutions accounted for 49% of total revenue, reaching a record €171.4 million.

The strong performance was supported by a 10% revenue growth in the company’s biopharmaceutical and diagnostic solutions divisions. Gross margin expanded by 120 basis points to 30.9%, and adjusted EBITDA margin increased by 70 basis points to 28.2%.

CEO Franco Stevanato commented, “We closed another solid quarter for fiscal year 2025, delivering a full-year positive performance driven by strong revenue growth, a favorable mix of high-value solutions, and margin expansion.”

For fiscal year 2026, Stevanato set an adjusted diluted EPS guidance of €0.59 to €0.63, with a midpoint of €0.61, slightly below the analyst consensus of €0.64.

The company expects revenue between €1.26 billion and €1.29 billion, with a midpoint of €1.275 billion, roughly in line with the consensus estimate of €1.28 billion. Adjusted EBITDA is projected to be between €331.8 million and €346.9 million.

The company noted that GLP-1 drugs accounted for approximately 19% to 20% of total revenue in 2025, reflecting its successful market share gains in the growing biopharmaceutical sector.

This article was translated with AI assistance. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.